Who Do We Serve?
Breast Cancer
Triple-Negative Breast Cancer (TNBC)
Ovarian cancer is often called the “silent killer” because over 70% of cases are diagnosed at an advanced stage, leading to a 5-year survival rate of only about 30% in late-stage cases, compared to over 90% when caught early.
OncoGaze™ detects HRD status at biopsy, helping connect Ovarian Cancer patients to the right treatments, faster.
BREAST Cancer Today
Triple-negative breast cancer (TNBC) accounts for approximately 10–15% of all breast cancer diagnoses in the United States, translating to an estimated 31,000 to 47,000 new cases annually, based on the projected 316,950 new female breast cancer cases in 2025. Globally, TNBC incidence is estimated at around 170,000 cases per year.
40%
HRD is prevalent in 40% of cases of Breast Cancer
Detecting HRD early can significantly impact patient outcomes by guiding timely use of targeted therapies
15%
Triple-negative breast cancer accounts for 10-15% of all breast cancer diagnoses in hte U.S.
47,000
cases/year U.S.
316,000
cases/year worldwide, all breast cancer
170,000
cases of TNBC in the U.S. annually
TNBC is more prevalent among younger women, particularly those under 40, and is disproportionately diagnosed in Black women, who have nearly twice the incidence rate compared to white women.
Who should get tested for HRD?
All TNBC and Metastatic Breast Cancer patients should be tested for HRD.
HRD plays a critical role in triple-negative breast cancer (TNBC), an aggressive subtype lacking hormone and HER2 targets. Identifying HRD enables use of targeted therapies like PARP inhibitors, which improve outcomes in eligible patients. Early detection of HRD is essential for guiding effective, personalized first-line treatment in TNBC.
Why does this matter?
HRD detection enables women with triple-negative and metastatic breast cancer to access targeted therapies like PARP inhibitors earlier—improving outcomes through personalized treatment aligned with tumor biology.
Acurion's OncoGaze™ delivers fast, accurate genomic insights from pathology slides—accelerating access to targeted therapy for Breast Cancer patients.
“Triple-negative breast cancer remains one of the most challenging subtypes we treat due to limited targeted options. Identifying HRD status early would meaningfully change clinical decision-making—allowing us to personalize first-line therapy with greater precision. If we could detect HRD from the initial biopsy, we’d be able to act faster and more effectively, ultimately improving outcomes for these high-risk patients.”
Ramez Eskander, MD
Clinical Trials Office Director, Clinical Professor Obstetrics & Gynecology, UC San Diego
MORE READING
[LINKS TO LITERATURE]
Let's move cancer care forward – together.
Explore how Acurion is driving immediate precision for optimal care. Contact us for a demo of OncoGaze™.